An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis-Reference-Cited by-同舟云学术

An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis

Published:2006-12 Issue:6 Volume:260 Page:577-585
ISSN:0954-6820
Container-title:Journal of Internal Medicine
language:en
Short-container-title:J Intern Med

Author:

AGARWAL A. K.,SILVER M. R.,REED J. E.,DHINGRA R. K.,LIU W.,VARMA N.,STEHMAN-BREEN C.

Publisher

Wiley

Subject

Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2796.2006.01723.x/fullpdf

Reference26 articles.

1. Quality of life in Chronic Kidney Disease (CKD): A cross-sectional analysis in the Renal Research Institute-CKD study

2. Anemia and health-related quality of life in adolescents with chronic kidney disease

3. Association of Chronic Kidney Disease and Anemia with Physical Capacity: The Heart and Soul Study

4. Traditional and Nontraditional Risk Factors Predict Coronary Heart Disease in Chronic Kidney Disease: Results from the Atherosclerosis Risk in Communities Study

5. Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis;Kidney Research and Clinical Practice;2024-05-31

2. Efficacy and safety of CKD-11101 (darbepoetin-alfa proposed biosimilar) compared with NESP in anaemic chronic kidney disease patients not on dialysis;Current Medical Research and Opinion;2019-01-17

3. Hepcidin in chronic kidney disease anemia;Vitamins and Hormones;2019

4. Development of Recombinant Erythropoietin and Erythropoietin Analogs;Textbook of Nephro-Endocrinology;2018

5. Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review;European Journal of Clinical Pharmacology;2016-07-21